Related Experiment Video
Updated: Aug 3, 2025
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis
Juan C Vargas-Zambrano1, Liana R Clark2, David R Johnson2
1Global Medical Evidence Generation, Sanofi, Lyon, France.
Insights
Maternal tetanus, diphtheria, and acellular pertussis (Tdap5) vaccination during pregnancy significantly protects infants from pertussis. This Tdap5 vaccine administered between 27 and 36 weeks gestation demonstrated 92.5% effectiveness in preventing infant pertussis.
Area of Science:
- Public Health
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Pertussis poses a significant risk to infants under two months old.
- Maternal vaccination during pregnancy is a key strategy to protect newborns.
- The specific effectiveness of Tdap5 (Adacel®) in pregnancy requires detailed analysis.
Purpose of the Study:
- To evaluate the effectiveness of the Tdap5 vaccine administered during pregnancy.
- To determine the efficacy of Tdap5 in preventing pertussis in infants younger than two months.
- To analyze product-specific vaccine effectiveness for Tdap5.
Main Methods:
- A case-control study was conducted using data from the CDC/EIP Network (2011-2014).
- The study analyzed Tdap5 vaccination effectiveness in pregnant individuals between 27 and 36 weeks gestation.
- Conditional logistic regression was used to estimate odds ratios and calculate vaccine effectiveness.
Main Results:
- Tdap5 vaccination during pregnancy between 27-36 weeks gestation showed 92.5% effectiveness (95% CI, 38.5%-99.1%) in preventing infant pertussis.
- Effectiveness against pertussis-related hospitalization could not be determined.
- Postpartum or late-term (less than 14 days before delivery) vaccination did not protect infants.
Conclusions:
- Tdap5 vaccination during pregnancy, specifically between 27 and 36 weeks gestation, is highly effective.
- This vaccination strategy provides crucial protection for young infants against pertussis.
- Optimal timing of maternal Tdap5 vaccination is essential for infant protection.
Objective:
To evaluate the effectiveness of the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine containing five pertussis components (Tdap5; Adacel®, Sanofi) when given during pregnancy at preventing pertussis in infants less than 2 months of age.
Methods:
The US Centers for Disease Control and Prevention (CDC), in collaboration with the Emerging Infections Program (EIP) Network, undertook a case-control study evaluating the effectiveness of Tdap vaccination in pregnancy against pertussis in infants less than 2 months of age based on data collected by the EIP Network from 2011 through 2014. The dataset from the CDC/EIP Network study was used to conduct this product-specific vaccine effectiveness analysis of Tdap5 vaccination in pregnancy to prevent disease in young infants. The main outcome of interest was vaccine effectiveness in infants whose pregnant parents were vaccinated with Tdap5 between 27 and 36 weeks' gestation, in accordance with the ideal timing for Tdap vaccination in pregnancy recommended by the US Advisory Committee on Immunization Practices. Odd ratios (ORs) and 95 % confidence intervals (CIs) were estimated using conditional logistic regression, and vaccine effectiveness was calculated as (1-OR) × 100 %.
Results:
There were 160 infant pertussis cases and 302 matched controls included in this Tdap5-specific study. Tdap5 effectiveness in preventing pertussis in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation was 92.5 % (95 % CI, 38.5 %-99.1 %). Effectiveness of Tdap5 against pertussis-related hospitalization in infants whose pregnant parents were vaccinated between 27 and 36 weeks' gestation could not be calculated due to lack of discordance among matched cases and controls. Vaccination of the parents after pregnancy or less than 14 days before delivery did not protect infants from pertussis.
Conclusions:
Tdap5 vaccination in pregnancy between 27 and 36 weeks' gestation is highly effective at protecting young infants from pertussis.
Study Registration:
ClinicalTrials.gov, NCT05040802.
More Related Videos
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
Related Concept Videos
01:51Vaccinations
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:31Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...